Hemant N. Joshi, PhD, MBA

Founder, TARA Innovations LLC, USA

Senior Advisor, Pharmaceutical Quality, Isha Therapeutics LLC

Hemant N. Joshi, Ph.D., MBA, Advisor Founder, TARA Innovations, LLC. Dr. Hemant Joshi is the founder of Tara Innovations LLC, a Pharmaceutical product development Contract Research Organization (CRO). He has over 27 years' experience as a Pharmaceutical Scientist. Tara is involved in product development, analysis and technology management. Tara has a history of providing effective solutions to complex pharmaceutical development problems in a timely manner. Prior to starting Tara, Dr. Joshi worked for pharmaceutical companies such as Glaxo (India), Bristol-Myers Squibb, Forest Labs, Barr Labs, and Spectrum Pharmaceuticals in the areas formulation development, development of analytical assays and finished products.

He was involved in the formulation development and scale-up of various types of dosage forms. Dr. Joshi has worked on many name brand products such as Stadol Nasal Spray (Butorphenol), Questran powder (Cholestyramine), Celexa tablets (Citalopram), Pravachol tablet (Pravastatin), Viagra nasal spray (Sildenafil), Retinoic acid capsules (Tretinoin), Fusilev Injection (Levoleucovorin), Serzone tablets (Nefazodone) etc. He has a passion for developing formulations with a desired rate of drug release and targeting the drugs to the site of action. Dr. Joshi has a particular interest in understanding in-vitro/invivo correlation.

TARA Innovations has developed two Ayurvedic products which have been approved by the Indian counterpart of the FDA, Drugs Controller General of India (DCGI). They are expected to be launched in 2016. Dr. Joshi obtained B.Pharm. and M.Pharm. from Bombay College of Pharmacy, India and a Ph.D. in Pharmaceutical Chemistry from University of Kansas. He received his MBA from Fairleigh Dickinson University. He is the author of many research articles. He writes columns on a regular basis in journals such as the Pharmaceutical Outsourcing (on NDAs) and American Pharmaceutical Review (on patents).